Even though the EGF ligands Nectin-4, HB-EGF and AREG have been described as rational targets for blood-based detection of ovarian cancer, their application as biomarkers for early-stage ovarian cancer so far has not been shown. This evidence concerns the gene EGF and ovarian cancer.